Q3 Earnings Estimate for Teleflex Issued By Zacks Research

Teleflex Incorporated (NYSE:TFX) – Zacks Research dropped their Q3 2024 earnings estimates for shares of Teleflex in a report released on Wednesday, October 23rd. Zacks Research analyst R. Department now anticipates that the medical technology company will post earnings of $3.36 per share for the quarter, down from their previous estimate of $3.37. The consensus estimate for Teleflex’s current full-year earnings is $13.97 per share. Zacks Research also issued estimates for Teleflex’s Q4 2024 earnings at $3.91 EPS, Q2 2025 earnings at $3.74 EPS, Q1 2026 earnings at $3.99 EPS and Q3 2026 earnings at $4.14 EPS.

Several other analysts have also recently issued reports on TFX. Piper Sandler raised shares of Teleflex from a “neutral” rating to an “overweight” rating and boosted their price objective for the company from $205.00 to $245.00 in a research note on Monday, July 1st. Royal Bank of Canada lifted their target price on shares of Teleflex from $260.00 to $275.00 and gave the company an “outperform” rating in a report on Tuesday, October 8th. Stephens boosted their price objective on shares of Teleflex from $275.00 to $290.00 and gave the stock an “overweight” rating in a report on Friday, August 2nd. Finally, Truist Financial boosted their price objective on shares of Teleflex from $247.00 to $255.00 and gave the stock a “hold” rating in a report on Monday, October 14th. Three investment analysts have rated the stock with a hold rating and six have issued a buy rating to the company. Based on data from MarketBeat, Teleflex presently has a consensus rating of “Moderate Buy” and a consensus price target of $268.86.

Teleflex Stock Down 0.8 %

TFX stock opened at $233.65 on Thursday. Teleflex has a one year low of $177.63 and a one year high of $257.85. The company has a 50 day moving average price of $241.03 and a two-hundred day moving average price of $223.68. The stock has a market capitalization of $11.01 billion, a P/E ratio of 41.95, a PEG ratio of 2.15 and a beta of 1.16. The company has a debt-to-equity ratio of 0.36, a quick ratio of 1.44 and a current ratio of 2.58.

Teleflex (NYSE:TFX) last released its earnings results on Thursday, August 1st. The medical technology company reported $3.42 EPS for the quarter, topping the consensus estimate of $3.33 by $0.09. The firm had revenue of $749.70 million during the quarter, compared to analysts’ expectations of $762.98 million. Teleflex had a net margin of 8.76% and a return on equity of 14.51%. Teleflex’s revenue for the quarter was up .9% on a year-over-year basis. During the same period in the previous year, the company earned $3.41 EPS.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently bought and sold shares of TFX. Janus Henderson Group PLC boosted its holdings in shares of Teleflex by 12.0% in the first quarter. Janus Henderson Group PLC now owns 5,409,317 shares of the medical technology company’s stock valued at $1,223,424,000 after acquiring an additional 581,312 shares in the last quarter. Point72 Asset Management L.P. lifted its position in shares of Teleflex by 564.3% in the 2nd quarter. Point72 Asset Management L.P. now owns 310,484 shares of the medical technology company’s stock valued at $65,304,000 after acquiring an additional 263,743 shares in the last quarter. Cooke & Bieler LP lifted its position in shares of Teleflex by 23.3% in the 2nd quarter. Cooke & Bieler LP now owns 912,797 shares of the medical technology company’s stock valued at $191,989,000 after acquiring an additional 172,335 shares in the last quarter. Ceredex Value Advisors LLC acquired a new position in Teleflex in the 2nd quarter valued at approximately $25,550,000. Finally, National Bank of Canada FI increased its stake in Teleflex by 1,008.2% in the 2nd quarter. National Bank of Canada FI now owns 115,343 shares of the medical technology company’s stock valued at $24,388,000 after buying an additional 104,935 shares during the period. Institutional investors own 95.62% of the company’s stock.

Insider Activity at Teleflex

In related news, Director Stuart A. Randle sold 2,674 shares of the business’s stock in a transaction dated Friday, August 16th. The shares were sold at an average price of $238.93, for a total transaction of $638,898.82. Following the completion of the sale, the director now owns 5,496 shares of the company’s stock, valued at $1,313,159.28. This represents a 0.00 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Insiders own 1.43% of the company’s stock.

Teleflex Announces Dividend

The business also recently announced a quarterly dividend, which was paid on Monday, September 16th. Stockholders of record on Thursday, August 15th were paid a $0.34 dividend. The ex-dividend date was Thursday, August 15th. This represents a $1.36 dividend on an annualized basis and a dividend yield of 0.58%. Teleflex’s dividend payout ratio (DPR) is presently 24.42%.

About Teleflex

Teleflex Incorporated designs, develops, manufactures, and supplies single-use medical devices for common diagnostic and therapeutic procedures in critical care and surgical applications worldwide. The company provides vascular access products that comprise Arrow branded catheters, catheter navigation and tip positioning systems, and intraosseous access systems for the administration of intravenous therapies, the measurement of blood pressure, and the withdrawal of blood samples through a single puncture site.